Browse CALR

Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum lumen Cytoplasm, cytosol Secreted, extracellular space, extracellular matrix Cell surface Sarcoplasmic reticulum lumen Note=Also found in cell surface (T cells), cytosol and extracellular matrix (PubMed:10358038). Associated with the lytic granules in the cytolytic T-lymphocytes.
Domain PF00262 Calreticulin family
Function

Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently with almost all of the monoglucosylated glycoproteins that are synthesized in the ER. Interacts with the DNA-binding domain of NR3C1 and mediates its nuclear export. Involved in maternal gene expression regulation. May participate in oocyte maturation via the regulation of calcium homeostasis (By similarity).

> Gene Ontology
 
Biological Process GO:0002396 MHC protein complex assembly
GO:0002397 MHC class I protein complex assembly
GO:0002407 dendritic cell chemotaxis
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I
GO:0002501 peptide antigen assembly with MHC protein complex
GO:0002502 peptide antigen assembly with MHC class I protein complex
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006260 DNA replication
GO:0006275 regulation of DNA replication
GO:0006417 regulation of translation
GO:0006457 protein folding
GO:0006611 protein export from nucleus
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006898 receptor-mediated endocytosis
GO:0006909 phagocytosis
GO:0006913 nucleocytoplasmic transport
GO:0006984 ER-nucleus signaling pathway
GO:0006986 response to unfolded protein
GO:0007050 cell cycle arrest
GO:0007126 meiotic nuclear division
GO:0007283 spermatogenesis
GO:0007507 heart development
GO:0007568 aging
GO:0007569 cell aging
GO:0009755 hormone-mediated signaling pathway
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010226 response to lithium ion
GO:0010608 posttranscriptional regulation of gene expression
GO:0010720 positive regulation of cell development
GO:0010721 negative regulation of cell development
GO:0010769 regulation of cell morphogenesis involved in differentiation
GO:0010770 positive regulation of cell morphogenesis involved in differentiation
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0014706 striated muscle tissue development
GO:0017148 negative regulation of translation
GO:0019882 antigen processing and presentation
GO:0022417 protein maturation by protein folding
GO:0022604 regulation of cell morphogenesis
GO:0030100 regulation of endocytosis
GO:0030335 positive regulation of cell migration
GO:0030518 intracellular steroid hormone receptor signaling pathway
GO:0030522 intracellular receptor signaling pathway
GO:0030595 leukocyte chemotaxis
GO:0030865 cortical cytoskeleton organization
GO:0030866 cortical actin cytoskeleton organization
GO:0030968 endoplasmic reticulum unfolded protein response
GO:0031589 cell-substrate adhesion
GO:0031647 regulation of protein stability
GO:0031958 corticosteroid receptor signaling pathway
GO:0032103 positive regulation of response to external stimulus
GO:0032355 response to estradiol
GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway
GO:0033144 negative regulation of intracellular steroid hormone receptor signaling pathway
GO:0033574 response to testosterone
GO:0034248 regulation of cellular amide metabolic process
GO:0034249 negative regulation of cellular amide metabolic process
GO:0034446 substrate adhesion-dependent cell spreading
GO:0034504 protein localization to nucleus
GO:0034620 cellular response to unfolded protein
GO:0034975 protein folding in endoplasmic reticulum
GO:0034976 response to endoplasmic reticulum stress
GO:0035051 cardiocyte differentiation
GO:0035966 response to topologically incorrect protein
GO:0035967 cellular response to topologically incorrect protein
GO:0036336 dendritic cell migration
GO:0036500 ATF6-mediated unfolded protein response
GO:0038061 NIK/NF-kappaB signaling
GO:0040017 positive regulation of locomotion
GO:0040020 regulation of meiotic nuclear division
GO:0042493 response to drug
GO:0042692 muscle cell differentiation
GO:0042921 glucocorticoid receptor signaling pathway
GO:0043401 steroid hormone mediated signaling pathway
GO:0045665 negative regulation of neuron differentiation
GO:0045740 positive regulation of DNA replication
GO:0045785 positive regulation of cell adhesion
GO:0045786 negative regulation of cell cycle
GO:0045787 positive regulation of cell cycle
GO:0045807 positive regulation of endocytosis
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048232 male gamete generation
GO:0048384 retinoic acid receptor signaling pathway
GO:0048385 regulation of retinoic acid receptor signaling pathway
GO:0048387 negative regulation of retinoic acid receptor signaling pathway
GO:0048545 response to steroid hormone
GO:0048738 cardiac muscle tissue development
GO:0050764 regulation of phagocytosis
GO:0050766 positive regulation of phagocytosis
GO:0050768 negative regulation of neurogenesis
GO:0050821 protein stabilization
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051146 striated muscle cell differentiation
GO:0051168 nuclear export
GO:0051169 nuclear transport
GO:0051208 sequestering of calcium ion
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051272 positive regulation of cellular component movement
GO:0051321 meiotic cell cycle
GO:0051445 regulation of meiotic cell cycle
GO:0051604 protein maturation
GO:0051783 regulation of nuclear division
GO:0051961 negative regulation of nervous system development
GO:0055007 cardiac muscle cell differentiation
GO:0055074 calcium ion homeostasis
GO:0060326 cell chemotaxis
GO:0060537 muscle tissue development
GO:0060627 regulation of vesicle-mediated transport
GO:0061077 chaperone-mediated protein folding
GO:0071241 cellular response to inorganic substance
GO:0071248 cellular response to metal ion
GO:0071285 cellular response to lithium ion
GO:0071383 cellular response to steroid hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0090398 cellular senescence
GO:1900024 regulation of substrate adhesion-dependent cell spreading
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901224 positive regulation of NIK/NF-kappaB signaling
GO:1901654 response to ketone
GO:1903046 meiotic cell cycle process
GO:2000147 positive regulation of cell motility
GO:2000241 regulation of reproductive process
GO:2000508 regulation of dendritic cell chemotaxis
GO:2000510 positive regulation of dendritic cell chemotaxis
Molecular Function GO:0001846 opsonin binding
GO:0001848 complement binding
GO:0001849 complement component C1q binding
GO:0001948 glycoprotein binding
GO:0003729 mRNA binding
GO:0005178 integrin binding
GO:0005506 iron ion binding
GO:0030246 carbohydrate binding
GO:0031625 ubiquitin protein ligase binding
GO:0033218 amide binding
GO:0035257 nuclear hormone receptor binding
GO:0035258 steroid hormone receptor binding
GO:0042277 peptide binding
GO:0042562 hormone binding
GO:0044183 protein binding involved in protein folding
GO:0044389 ubiquitin-like protein ligase binding
GO:0050681 androgen receptor binding
GO:0050839 cell adhesion molecule binding
GO:0051082 unfolded protein binding
GO:0051087 chaperone binding
GO:0051427 hormone receptor binding
Cellular Component GO:0001669 acrosomal vesicle
GO:0005578 proteinaceous extracellular matrix
GO:0005788 endoplasmic reticulum lumen
GO:0005790 smooth endoplasmic reticulum
GO:0005844 polysome
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0009897 external side of plasma membrane
GO:0016528 sarcoplasm
GO:0016529 sarcoplasmic reticulum
GO:0030055 cell-substrate junction
GO:0030139 endocytic vesicle
GO:0030141 secretory granule
GO:0030176 integral component of endoplasmic reticulum membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
GO:0031983 vesicle lumen
GO:0033018 sarcoplasmic reticulum lumen
GO:0042824 MHC class I peptide loading complex
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0071556 integral component of lumenal side of endoplasmic reticulum membrane
GO:0071682 endocytic vesicle lumen
GO:0097223 sperm part
GO:0098552 side of membrane
GO:0098553 lumenal side of endoplasmic reticulum membrane
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04141 Protein processing in endoplasmic reticulum
hsa04145 Phagosome
hsa04612 Antigen processing and presentation
Reactome R-HSA-381183: ATF6 (ATF6-alpha) activates chaperone genes
R-HSA-381033: ATF6 (ATF6-alpha) activates chaperones
R-HSA-1280218: Adaptive Immune System
R-HSA-983170: Antigen Presentation
R-HSA-1236975: Antigen processing-Cross presentation
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-168316: Assembly of Viral Components at the Budding Site
R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-901042: Calnexin/calreticulin cycle
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-1643685: Disease
R-HSA-1236974: ER-Phagosome pathway
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-168254: Influenza Infection
R-HSA-168255: Influenza Life Cycle
R-HSA-392499: Metabolism of proteins
R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-597592: Post-translational protein modification
R-HSA-3000480: Scavenging by Class A Receptors
R-HSA-3000484: Scavenging by Class F Receptors
R-HSA-381119: Unfolded Protein Response (UPR)
R-HSA-5653656: Vesicle-mediated transport
R-HSA-168268: Virus Assembly and Release
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CALR and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CALR and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
21178137Bladder CarcinomaPromote immunityHere, we identified calreticulin as a pro-phagocytic signal that was highly expressed on the surface of several human cancers, but was minimally expressed on most normal cells. Increased CD47 expression correlated with high amounts of calreticulin on cancer cells and was necessary for protection from calreticulin-mediated phagocytosis.
24893628Skin Basal Cell CarcinomaPromote immunityWe examined the combination of topical imiquimod with intramuscular administration of CRT/E7, a therapeutic human papillomavirus (HPV) vaccine comprised of a naked DNA vector expressing calreticulin fused to HPV16 E7.
27803062Acute Myeloid LeukemiaPromote immunityIn these patients, high levels of surface-exposed CRT correlated with an increased proportion of natural killer cells and effector memory CD4+ and CD8+ T cells in the periphery. Moreover, CRT exposure on the plasma membrane of malignant blasts positively correlated with the frequency of circulating T cells specific for leukemia-associated antigens, indicating that ecto-CRT favors the initiation of anticancer immunity in patients with AML.
21805477Hepatocellular CarcinomaPromote immunity (infiltration)Calreticulin (CRT), a chaperone protein mainly located in the endoplasmic reticulum, has been shown to exert anti-angiogenic activity and inhibit tumor growth. Here, we demonstrate that in addition to inhibiting angiogenesis, CRT also enhances the expression of both ICAM-1 and VCAM-1 on tumor endothelial cells. This expression results in enhanced leukocyte-endothelial cell interactions and increased lymphocyte infiltration into tumors.
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CALR in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.82; FDR: 0.01650 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.59 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 7.55; FDR: 0.000 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 6.89; FDR: 0.001 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CALR in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1320.518
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2230.957
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.070.982
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1270.756
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0410.989
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2360.95
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0480.937
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2440.925
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3670.899
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3710.902
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.80.862
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1170.0887
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CALR in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277304.1-4.10.561
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275905.1-5.10.549
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CALR. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CALR. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CALR.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CALR. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CALR expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CALR and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCALR
Namecalreticulin
Aliases RO; cC1qR; FLJ26680; Sicca syndrome antigen A (autoantigen Ro; calreticulin); autoantigen Ro; HEL-S-99n; CRP ......
Chromosomal Location19p13.3-p13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CALR collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CALR.
ID Name Drug Type Targets #Targets
DB00025Antihemophilic factor, human recombinantBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11
DB00031TenecteplaseBiotechANXA2, CALR, CANX, CLEC3B, FGA, KRT8, LRP1, PLAUR, PLG, SERPINB2, ......11
DB01065MelatoninSmall MoleculeASMT, CALR, EPX, ESR1, MPO, MTNR1A, MTNR1B, NQO2, RORB9
DB06245LanoteplaseBiotechANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......17
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141
DB11093Calcium CitrateSmall MoleculeCADPS, CADPS2, CALB2, CALR, CALR3, CANX, CAPS, CASQ1, CASQ2, CASR, ......29
DB11348Calcium PhosphateSmall MoleculeCADPS, CADPS2, CALB2, CALR, CALR3, CANX, CAPS, CASQ1, CASQ2, CASR, ......29
DB13998Lonoctocog alfaBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11
DB13999Moroctocog alfaBiotechASGR2, CALR, CANX, F10, F9, HSPA5, LMAN1, LRP1, MCFD2, PHYH, VWF11